Venrock Healthcare Capital Partners III, L.P. → Relmada Therapeutics, Inc. RLMD

Stake: — Shares: — Class: Common Stock, $0.001 par value per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 25/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (8.5 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

4 transactions

4 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 8.54

12,179,982 shares short · -9.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $905K

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-09-10	Shenouda Maged	officer	Buy	79,800	$4.25	$339K
2026-09-10	TRAVERSA SERGIO	director, officer	Buy	100,000	$4.10	$410K
2026-09-09	Shenouda Maged	officer	Buy	120,200	$4.20	$505K
2026-09-09	TRAVERSA SERGIO	director, officer	Buy	100,000	$4.18	$418K

Other 13D/G Filings on Relmada Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2026-06-22	SCHEDULE 13G	MILLENNIUM MANAGEMENT LLC	—	—	view →

Other Filings by Venrock Healthcare Capital Partners III, L.P.

Filed	Form	Issuer	Stake	Shares
2026-09-21	SCHEDULE 13G	X4 Pharmaceuticals, Inc.	—	—	view →
2026-09-15	SCHEDULE 13D	Korsana Biosciences, Inc.	9.90%	4,552,277	view →
2026-09-08	SCHEDULE 13D/A	APOGEE THERAPEUTICS, INC.	—	0	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →